Claims
- 1. A bacterial delivery system which comprises live, attenuated invasive Salmonella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA comprises at least one nucleic acid control sequence operably linked to a heterologous nucleic acid sequence to control expression of said heterologous genes.
- 2. The bacterial delivery system of claim 1, wherein said Salmonella is Salmonella typhi.
- 3. The bacterial delivery system of claim 2, wherein said bacteria are attenuated via an attenuating mutation in an aro gene, an asd gene, an htrA gene or in a combination of one or more of these genes.
- 4. The bacterial delivery system of claim 3, wherein said bacteria have an attenuating mutation in an aro gene and an asd gene.
- 5. The bacterial delivery system of claim 4, wherein said aro gene is aroA and/or aroD.
- 6. The bacterial delivery system of claim 3, wherein said bacteria have an attenuating mutation in an aro gene and an htrA gene.
- 7. The bacterial delivery system of claim 6, wherein said aro gene is aroA and/or aroD.
- 8. The bacterial delivery system of claim 1, wherein said heterologous nucleic acid sequence comprises one or more coding regions of a gene and wherein each coding region of said heterologous nucleic acid sequence can be expressed separately or as an operon.
- 9. The bacterial delivery system of claim 8, wherein said heterologous nucleic acid sequence encodes an antigen or an antigenic fragment of a protein from a viral pathogen.
- 10. The bacterial delivery system of claim 9, wherein said viral pathogen is HIV.
- 11. The bacterial delivery system of any one of claims 1-8, wherein said heterologous nucleic acid sequence encodes one or more HIV genes selected from the group consisting of env, gag, pol, or an antigenic fragment of a protein encoded by any one of said genes, wherein said genes are from an HIV isolate and/or from a consensus sequence of HIV isolates.
- 12. The bacterial delivery system of claim 11, wherein said heterologous nucleic acid sequence encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
- 13. A method for introducing and expressing a gene in an animal which comprises infecting said animal with the bacterial delivery system of claim 11, and thereby obtaining expression of a gene product encoded by said heterologous nucleic acid sequence in said animal.
- 14. The method of claim 13 wherein infecting occurs by an intranasal delivery route.
- 15. A method for inducing an immune response in an animal which comprises infecting said animal with live, attenuated invasive Salmonella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA encodes at least one antigen or antigenic fragment of a protein, and wherein said antigen or said fragment is expressed at a level sufficient to stimulate an immune response to said antigen or said fragment.
- 16. The method of claim 15, wherein said Salmonella is Salmonella typhi.
- 17. The method of claim 16, wherein said bacteria are attenuated via an attenuating mutation in an aro gene, an asd gene, an htrA gene or in a combination of one or more of these genes.
- 18. The method of claim 17, wherein said bacteria have an attenuating mutation in an aro gene and an asd gene.
- 19. The method of claim 18, wherein said aro gene is aroA and/or aroD.
- 20. The method of claim 17, wherein said bacteria have an attenuating mutation in an aro gene and an htrA gene.
- 21. The method of claim 20, wherein said aro gene is aroA and/or aroD.
- 22. The method of claim 15, wherein said antigen or said antigenic fragment is a tumor antigen, a transplantation antigen or an autoimmune antigen.
- 23. The method of any one of claims 15-21, wherein said antigen or said antigenic fragment of a protein is from a viral pathogen, a bacterial pathogen or a parasitic pathogen.
- 24. The method of claim 23, wherein said viral pathogen is HIV.
- 25. The method of any one of claims 15-21, wherein said antigen or antigenic fragment is encoded by one or more HIV genes selected from the group consisting of env, gag, pol, nef, tat, or rev, wherein said HIV genes are from an HIV isolate and/or from a consensus sequence of HIV isolates.
- 26. The method of claim 25, wherein said alphavirus replicon DNA encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
- 27. The method of any one of claims 15-21, wherein infecting occurs by an intranasal delivery route.
- 28. The method of claim 25, wherein infecting occurs by an intranasal delivery route.
- 29. The method of claim 26, wherein infecting occurs by an intranasal delivery route.
- 30. A bacterial delivery system which comprises live, attenuated invasive Shigella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA comprises at least one nucleic acid control sequence operably linked to a heterologous nucleic acid sequence to control expression of said heterologous genes.
- 31. The bacterial delivery system of claim 30, wherein said Shigella is Shigella flexneri or Shigella flexneri 2a
- 32. The bacterial delivery system of claim 31, wherein said bacteria are attenuated via an attenuating mutation in an aro gene, a gua gene, a virG gene or in a combination of one or more of these genes.
- 33. The bacterial delivery system of claim 32, wherein said bacteria have an attenuating mutation in an aro gene and a virg gene.
- 34. The bacterial delivery system of claim 33, wherein said aro gene is aroA and/or aroD.
- 35. The bacterial delivery system of claim 32, wherein said bacteria have an attenuating mutation in a gua gene and a virG gene.
- 36. The bacterial delivery system of claim 35, wherein said aro gene is aroA and/or aroD.
- 37. The bacterial delivery system of claim 30, wherein said heterologous nucleic acid sequence comprises one or more coding regions of a gene and wherein each coding region of said heterologous nucleic acid sequence can be expressed separately or as an operon.
- 38. The bacterial delivery system of claim 37, wherein said heterologous nucleic acid sequence encodes an antigen or an antigenic fragment of a protein from a viral pathogen, a bacterial pathogen or a parasitic pathogen.
- 39. The bacterial delivery system of claim 38, wherein said viral pathogen is HIV.
- 40. The bacterial delivery system of any one of claims 30-37, wherein said heterologous nucleic acid sequence encodes one or more HIV genes selected from the group consisting of env, gag, pol, or an antigenic fragment of a protein encoded by any one of said genes, wherein said genes are from an HIV isolate AND/or from a consensus sequence of HIV isolates.
- 41. The bacterial delivery system of claim 40, wherein said heterologous nucleic acid sequence encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
- 42. A method for introducing and expressing a gene in an animal which comprises infecting said animal with the bacterial delivery system of claim 40, and thereby obtaining expression of a gene product encoded by said heterologous nucleic acid sequence in said animal.
- 43. The method of claim 42, wherein infecting occurs by an intranasal delivery route.
- 44. A method for inducing an immune response in an animal which comprises infecting said animal with live, attenuated invasive Shigella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA encodes at least one antigen or antigenic fragment of a protein, and wherein said antigen or said fragment is expressed at a level sufficient to stimulate an immune response to said antigen or said fragment.
- 45. The method of claim 44, wherein said Shigella is Shigella flexneri or Shigella flexneri 2a.
- 46. The method of claim 45, wherein said bacteria are attenuated via an attenuating mutation in an aro gene, a gua gene, a virG gene or in a combination of one or more of these genes.
- 47. The method of claim 46, wherein said bacteria have an attenuating mutation in an aro gene and a virG gene.
- 48. The method of claim 47, wherein said aro gene is aroA and/or aroD.
- 49. The method of claim 48, wherein said bacteria have an attenuating mutation in a gua gene and a virG gene.
- 50. The method of claim 49, wherein said aro gene is aroA and/or aroD.
- 51. The method of claim 44, wherein said antigen or said antigenic fragment is a tumor antigen, a transplantation antigen or an autoimmune antigen.
- 52. The method of any one of claims 44-50, wherein said antigen or said antigenic fragment of a protein is from a viral pathogen, a bacterial pathogen or a parasitic pathogen.
- 53. The method of claim 52, wherein said viral pathogen is HIV.
- 54. The method of claim of any one of claims 44-50, wherein said antigen or antigenic fragment is encoded by one or more HIV genes selected from the group consisting of env, gag, pol, nef, tat, or rev, wherein said HIV genes are from an HIV isolate and/or from a consensus sequence of HIV isolates.
- 55. The method of claim 54, wherein said alphavirus replicon DNA encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
- 56. The method of any one of claims 44-50, wherein infecting occurs by an intranasal delivery route.
- 57. The method of claim 54, wherein infecting occurs by an intranasal delivery route.
- 58. The method of claim 55, wherein infecting occurs by an intranasal delivery route.
Parent Case Info
[0001] This application is a continuation of U.S. Ser. No. 09/697,236 filed Oct. 26, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60161448 |
Oct 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09697236 |
Oct 2000 |
US |
Child |
10357095 |
Feb 2003 |
US |